FindTrial
Sign In

A Retrospective Study on Efficacy Evaluation of Anlotinib Combined with Temozolomide in the Treatment of Recurrent Glioma Based on Real-World Data

A Retrospective Study on Efficacy Evaluation of Anlotinib Combined with Temozolomide in the Treatment of Recurrent Glioma Based on Real-World Data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112913
Enrollment
Unknown
Registered
2025-11-20
Start date
2025-11-20
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Total transcranial glioma resection; 2. Pathological diagnosis after surgery confirmed glioma; 3. Standard post-operative treatment was administered (concurrent radiotherapy + temozolomide chemotherapy, followed by 6 months of adjuvant temozolomide chemotherapy); 4. Glioma recurrence was confirmed by imaging or pathology; 5. After recurrence, treatment with anlotinib + temozolomide was initiated.

Exclusion criteria

Exclusion criteria: 1. Unclear diagnosis;2.No histological pathological examination results;3. Incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival (PFS);—

Secondary

MeasureTime frame
Overall Survival (OS);Adverse Reactions (ARs);—

Countries

China

Contacts

Public ContactFei Li

The First Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army

feifly7887@126.com+86 138 8393 3419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026